Anthrax News and Research

RSS
Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.

Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
Underestimating cough duration may skew antibiotic perceptions

Underestimating cough duration may skew antibiotic perceptions

Soligenix's OrbeShield granted FDA oral BDP orphan drug designation

Soligenix's OrbeShield granted FDA oral BDP orphan drug designation

Report: States underprepared to meet public health needs during a crisis

Report: States underprepared to meet public health needs during a crisis

US FDA approves raxibacumab for treating inhalational anthrax

US FDA approves raxibacumab for treating inhalational anthrax

FDA approves GSK’s raxibacumab to treat inhalational anthrax

FDA approves GSK’s raxibacumab to treat inhalational anthrax

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Paxvax PXVX0200 cholera vaccine demonstrates safety and immunogenicity in Phase 1 clinical trial

Paxvax PXVX0200 cholera vaccine demonstrates safety and immunogenicity in Phase 1 clinical trial

Soligenix receives FDA Fast Track designation for SGX203 to treat pediatric Crohn's disease

Soligenix receives FDA Fast Track designation for SGX203 to treat pediatric Crohn's disease

Emergent receives BARDA contract to advance development of novel rPA anthrax vaccine

Emergent receives BARDA contract to advance development of novel rPA anthrax vaccine

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

Soligenix’s RiVax induces greater ricin neutralizing antibody levels in humans

Soligenix’s RiVax induces greater ricin neutralizing antibody levels in humans

Detect-to-Protect project to measure performance of new sensors for biological agents

Detect-to-Protect project to measure performance of new sensors for biological agents

Researchers reveal possible drug targets to combat anthrax

Researchers reveal possible drug targets to combat anthrax

PharmAthene receives clinical hold order from FDA for SparVax rPA anthrax vaccine program

PharmAthene receives clinical hold order from FDA for SparVax rPA anthrax vaccine program

University of Nevada researcher to optimize new rapid test for melioidosis

University of Nevada researcher to optimize new rapid test for melioidosis

FDA acknowledges receipt of resubmission of Human Genome Sciences’ raxibacumab BLA

FDA acknowledges receipt of resubmission of Human Genome Sciences’ raxibacumab BLA

Study: 13 zoonoses responsible for 2.4B cases of human illness per year

Study: 13 zoonoses responsible for 2.4B cases of human illness per year

iBio expands iBioModulator portfolio with allowance of patent for anthrax vaccines

iBio expands iBioModulator portfolio with allowance of patent for anthrax vaccines

Scientists image structure of bacterium protein coat

Scientists image structure of bacterium protein coat